Location History:
- Chaplehall, GB (2003)
- Airdrie, GB (2009)
- Newhouse-Scotland, GB (2010)
Company Filing History:
Years Active: 2003-2010
Title: The Innovative Contributions of David John Miller
Introduction
David John Miller is a notable inventor based in Airdrie, GB, recognized for his significant contributions to the field of pharmaceuticals. With a total of three patents to his name, Miller has focused on developing innovative solutions for central nervous system disorders. His work has the potential to impact the treatment of various neurological conditions.
Latest Patents
Miller's latest patents include groundbreaking compounds aimed at addressing critical health issues. One of his notable inventions is the 1-arylsulfonyl-3-substituted indole and indoline derivatives, which are useful in the treatment of central nervous system disorders. This invention relates to derivatives that can be utilized in pharmaceutical compositions for treating conditions such as psychosis, schizophrenia, manic depression, and Alzheimer's disease.
Another significant patent involves spiro[2H-1-benzopyran-2,4'-piperidine] derivatives, which serve as glycine transport inhibitors. This invention also includes pharmaceutical compositions that utilize these derivatives for therapeutic applications, particularly in treating CNS disorders.
Career Highlights
Throughout his career, David John Miller has worked with prominent companies in the pharmaceutical industry, including N.V. Organon and Akzo Nobel. His experience in these organizations has contributed to his expertise in developing innovative treatments for complex health issues.
Collaborations
Miller has collaborated with several professionals in his field, including Samuel George Gibson and Daniel Spinks. These collaborations have likely enhanced his research and development efforts, leading to the successful creation of his patented inventions.
Conclusion
David John Miller's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving treatments for central nervous system disorders. His work continues to pave the way for advancements in medical science and patient care.